Temporal proteomic analysis of HIV infection reveals remodelling of the host phosphoproteome by lentiviral Vif variants

Viruses manipulate host factors to enhance their replication and evade cellular restriction. We used multiplex tandem mass tag (TMT)-based whole cell proteomics to perform a comprehensive time course analysis of >6500 viral and cellular proteins during HIV infection. To enable specific functional predictions, we categorized cellular proteins regulated by HIV according to their patterns of temporal expression. We focussed on proteins depleted with similar kinetics to APOBEC3C, and found the viral accessory protein Vif to be necessary and sufficient for CUL5-dependent proteasomal degradation of all members of the B56 family of regulatory subunits of the key cellular phosphatase PP2A (PPP2R5A-E). Quantitative phosphoproteomic analysis of HIV-infected cells confirmed Vif-dependent hyperphosphorylation of >200 cellular proteins, particularly substrates of the aurora kinases. The ability of Vif to target PPP2R5 subunits is found in primate and non-primate lentiviral lineages, and remodeling of the cellular phosphoproteome is therefore a second ancient and conserved Vif function.This work was supported by a Wellcome Trust PRF (101835/Z/13/Z) to PJL and RTF to NJM (093964/Z/10/Z), NHSBT and the NIHR Cambridge BRC, a Wellcome Trust Strategic Award to CIMR, and the Addenbrooke’s Charitable Trust

Reducing drug related deaths : a pre-implementation assessment of knowledge,barriers and enablers for naloxone distribution through general practice

Peer reviewedPublisher PD

The Nearby Type Ibn Supernova 2015G: Signatures of Asymmetry and Progenitor Constraints

SN 2015G is the nearest known SN Ibn to date at 23.2 Mpc and it has proven itself a truly remarkable example of this rare subclass. We present the results of an extensive observational campaign including data from radio through ultraviolet wavelengths. SN 2015G was asymmetric, showing late-time nebular lines redshifted by 1000 km/s. It shared many features with the prototypical SN Ibn 2006jc, including extremely strong He I emission lines and a late-time blue pseudocontinuum. The young SN 2015G showed narrow P-Cygni profiles of He I, but never in its evolution did it show any signature of hydrogen - arguing for a dense, ionized, and hydrogen-free circumstellar medium moving outward with a velocity of 1000 km/s and created by relatively recent mass loss from the progenitor star. Ultraviolet through infrared observations show that the fading SN 2015G (which was probably discovered some 20 days post-peak) had a spectral energy distribution that was well described by a simple, single-component blackbody. Archival HST images provide upper limits on the luminosity of SN 2015G's progenitor, while nondetections of any luminous radio afterglow and optical nondetections of outbursts over the past two decades provide constraints upon its mass-loss history

Effect of Functional Capacity Evaluation information on the judgment of physicians about physical work ability in the context of disability claims

Purpose To test whether Functional Capacity Evaluation (FCE) information lead insurance physicians (IPs) to change their judgment about the physical work ability of claimants with musculoskeletal disorders (MSDs). Methods Twenty-seven IPs scored twice the physical work ability of two claimants for 12 specified activities, using a visual analogue scale. One claimant performed an FCE, the other served as a control. Outcome measure was the difference between experimental and control group in number of shifts in the physical work ability for the total of 12 specified activities. Results The IPs changed their judgment about the work ability 141 times when using FCE information compared to 102 times when not using this information (P-value = 0.001), both in the direction of more and less ability. Conclusions The IPs change their judgment of the physical work ability of claimants with MSDs in the context of disability claim procedures more often when FCE information is provide

Anti-tumor necrosis factor-Α antibody treatment reduces pulmonary inflammation and methacholine hyper-responsiveness in a murine asthma model induced by house dust

Background/Aims Recent studies documented that sensitization and exposure to cockroach allergens significantly increase children's asthma morbidity as well as severity, especially among inner city children. TNF-Α has been postulated to be a critical mediator directly contributing to the bronchopulmonary inflammation and airway hyper-responsiveness in asthma. This study investigated whether an anti-TNF-Α antibody would inhibit pulmonary inflammation and methacholine (Mch) hyper-responsiveness in a mouse model of asthma induced by a house dust extract containing both endotoxin and cockroach allergens. Methods A house dust sample was extracted with phosphate-buffered saline and then used for immunization and two additional pulmonary challenges of BALB/c mice. Mice were treated with an intravenous injection of anti-TNF-Α antibody or control antibody 1  h before each pulmonary challenge. Results In a kinetic study, TNF-Α levels within the bronchoalveolar lavage (BAL) fluid increased quickly peaking at 2 h while BAL levels of IL-4, IL-5, and IL-13 peaked at later time-points. Mch hyper-responsiveness was measured 24 h after the last challenge, and mice were killed 24 h later. TNF inhibition resulted in an augmentation of these Th2 cytokines. However, the allergic pulmonary inflammation was significantly reduced by anti-TNF-Α antibody treatment as demonstrated by a substantial reduction in the number of BAL eosinophils, lymphocytes, macrophages, and neutrophils compared with rat IgG-treated mice. Mch hyper-responsiveness was also significantly reduced in anti-TNF-Α antibody-treated mice and the pulmonary histology was also significantly improved. Inhibition of TNF significantly reduced eotaxin levels within the lung, suggesting a potential mechanism for the beneficial effects. These data indicate that anti-TNF-Α antibody can reduce the inflammation and pathophysiology of asthma in a murine model of asthma induced by a house dust extract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/73609/1/j.1365-2222.2005.02407.x.pd

DISCOVERY AND EARLY MULTI-WAVELENGTH MEASUREMENTS OF THE ENERGETIC TYPE IC SUPERNOVA PTF12GZK: A MASSIVE-STAR EXPLOSION IN A DWARF HOST GALAXY

We present the discovery and extensive early-time observations of the Type Ic supernova (SN) PTF12gzk. Our light curves show a rise of 0.8 mag within 2.5 hr. Power-law fits (f(t)∝(t – t 0) n ) to these data constrain the explosion date to within one day. We cannot rule out a quadratic fireball model, but higher values of n are possible as well for larger areas in the fit parameter space. Our bolometric light curve and a dense spectral sequence are used to estimate the physical parameters of the exploding star and of the explosion. We show that the photometric evolution of PTF12gzk is slower than that of most SNe Ic. The high ejecta expansion velocities we measure (~30, 000 km s–1 derived from line minima four days after explosion) are similar to the observed velocities of broad-lined SNe Ic associated with gamma-ray bursts (GRBs) rather than to normal SN Ic velocities. Yet, this SN does not show the persistent broad lines that are typical of broad-lined SNe Ic. The host-galaxy characteristics are also consistent with GRB-SN hosts, and not with normal SN Ic hosts. By comparison with the spectroscopically similar SN 2004aw, we suggest that the observed properties of PTF12gzk indicate an initial progenitor mass of 25-35 M ☉ and a large ((5-10) × 1051 erg) kinetic energy, the later being close to the regime of GRB-SN properties

Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

The response to the coronavirus disease 2019 (COVID-19) pandemic has been hampered by lack of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral therapy. Here we report the use of remdesivir in a patient with COVID-19 and the prototypic genetic antibody deficiency X-linked agammaglobulinaemia (XLA). Despite evidence of complement activation and a robust T cell response, the patient developed persistent SARS-CoV-2 pneumonitis, without progressing to multi-organ involvement. This unusual clinical course is consistent with a contribution of antibodies to both viral clearance and progression to severe disease. In the absence of these confounders, we take an experimental medicine approach to examine the in vivo utility of remdesivir. Over two independent courses of treatment, we observe a temporally correlated clinical and virological response, leading to clinical resolution and viral clearance, with no evidence of acquired drug resistance. We therefore provide evidence for the antiviral efficacy of remdesivir in vivo, and its potential benefit in selected patients